ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0389

An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis

Alessandra Alongi1, Hermine Brunner2, Angelo Ravelli3, Tadej Avcin4, Michael Beresford5, RUBEN BURGOS-VARGAS6, Ruben Cuttica7, Raju Khubchandani8, Ronald laxer9, Seza Özen10, Ross Petty11, Carol Wallace12, Nico Wulffraat13, Silvia Magni-Manzoni14, Marija Jelusic15, Alessandro Consolaro16, Jordi anton17, Gerd Horneff18, Mia Glerup19, Giovanni Filocamo20, Gabriele Simonini21, ADELE CIVINO22, Agustin Remesal23, Silvia Scala24, Angela Pistorio25, Daniel Lovell2, Alberto Martini26 and Nicolino Ruperto27, 1Università Milano Bicocca, Milan, Italy, Milano, Italy, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, 4University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia, 5Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, 6Department of Rheumatology, Hospital General de Mexico, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de México, Mexico, 7Hospital Pedro de Elizalde, Buenos Aires, Argentina, 8Jaslok Hospital and Research Center, Mumbai, India, 9The Hospital for Sick Children, Toronto, ON, Canada, 10Hacettepe University Medical Faculty, Ankara, Turkey, 11British Columbia Children’s Hospital, University of British Columbia, Vancouver, ON, Canada, 12Seattle Children's Hospital, University of Washington, Seattle, WA, 13Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 14Bambino Gesù IRCCS Children's Hospital, Rome, Italy, 15University Hospital Centre Zagreb, Zagreb, Croatia, 16IRCCS Istituto Giannina Gaslini, Genoa, Italy, 17Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, 18Asklepios Klinik, Hamburg, Germany, 19Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, 20Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 21Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 22Department of Pediatric Immunology and Rheumatology, LECCE, Italy, 23Hospital Universitario La Paz, Madrid, Spain, 24Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 25Servizio di Epidemiologia e Biostatistica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 26Università degli Studi di Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 27Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy

Meeting: ACR Convergence 2025

Keywords: classification criteria, Juvenile idiopathic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To improve the current classification criteria for juvenile idiopathic arthritis (JIA), a multi-step initiative coordinated by PRINTO was launched in 2015, starting with a consensus process that culminated in the proposal of the preliminary PRINTO JIA classification criteria. The steps include a large-scale prospective data collection of patients with new-onset JIA and the ongoing validation of evidence-based criteria. To initiate the validation phase, an international Delphi survey was conducted among pediatric rheumatologists to identify the most relevant categories and candidate variables for subsequent data collection. To identify consensus-based categories and variable sets for the evidence-based revision of JIA classification criteria.

Methods: An invitation to participate in two Delphi rounds was sent to PRINTO/PRCSG membership starting in 2020. In Round 1, participants evaluated each ILAR category plus the additional category ‘Early Onset ANA Positive Arthritis’, indicating whether to retain or discard it, and suggesting revised names. They also listed variables used in practice to diagnose each category. In Round 2, participants re-evaluated each category for retention and ranked the top three preferred names and the ten most useful variables for the category-specific diagnosis among those identified in Round 1. Based on the ranking, a median score for each variable was calculated. Variables falling above the 75th percentile of the score were identified for each category.

Results: 434 physicians responded in Round 1 and 884 in Round 2. Votes to retain the ILAR categories were 236 (73%) for Systemic arthritis, 218 (70%) for Oligoarthritis, 209 (69%) for Polyarthritis Rheumatoid Factor (RF) negative, 276 (92%) for Polyarthritis RF positive, 188 (66%) for Psoriatic arthritis, 225 (78%) for Enthesitis-related arthritis (ERA), 183 (67%) for Early-onset ANA-positive JIA, and 142 (53%) for Other arthritis. Top ranking labels for each new category were ‘Juvenile-onset Still disease’, ‘Oligoarticular JIA’, ‘Juvenile polyarthritis’, ‘JIA RF positive or anti-CCP positive’, ‘Juvenile psoriatic arthritis’, ‘Early onset spondyloarthritis’, ‘ANA positive juvenile arthritis’ and ‘Unclassified JIA’. The variables identified as most useful for the diagnosis (in the top quartile of the score) were 15 for Systemic arthritis, 31 for Oligoarthritis, 33 for Polyarthritis RF negative, 33 for Polyarthritis RF positive, 45 for ERA, 26 for Psoriatic arthritis, 27 for Early-onset ANA-positive JIA and 19 for Other arthritis.

Conclusion: The study yielded consensus-based categories to be considered in the new classification criteria and identified candidate variables to be included in the ongoing step of the project, namely the evidence-based validation of new classification criteria for JIA based on real new-onset patients’ data.


Disclosures: A. Alongi: None; H. Brunner: AbbVie, 2, AstraZeneca-Medimmune, 2, Biogen, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, EMD Serono, 2, F. Hoffmann-La Roche, 2, Genentech, 5, GlaxoSmithKline, 2, Merck, 2, Novartis, 2, Pfizer, 2, 5, Sanofi, 2, UCB, 2; A. Ravelli: AbbVie, 2, 5, 6, Alexion, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Galapagos, 2, 5, 6, Johnson & Johnson, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, SOBI, 2, 5, 6; T. Avcin: Novartis, 6, Octapharma, 1, 6, Pfizer, 6, Takeda, 6; M. Beresford: Novartis, 5; R. BURGOS-VARGAS: None; R. Cuttica: None; R. Khubchandani: None; R. laxer: Akros pharma, 2, Eli Lilly Canada, 2, Novartis, 2, Sanofi, 2; S. Özen: Novartis, 6, Pfizer, 6, Sobi, 6; R. Petty: None; C. Wallace: None; N. Wulffraat: None; S. Magni-Manzoni: None; M. Jelusic: None; A. Consolaro: None; J. anton: Sobi, 1, 5, 6; G. Horneff: Janssen, 5, MSD, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, Sanofi, 6; M. Glerup: None; G. Filocamo: None; G. Simonini: None; A. CIVINO: None; A. Remesal: None; S. Scala: None; A. Pistorio: None; D. Lovell: AbbVie, 2, Bristol-Myers Squibb(BMS), 2, Canadian Arthritis Society, 12, DSMB memberNIH-NIAMS and NIAID, Canadian Arthritis Society, Novartis, 2; A. Martini: None; N. Ruperto: Abbvie, 2, 6, AClaris, 2, 6, AlfaSigma, 2, 6, Amgen, 2, 6, AstraZeneca, 2, 6, Aurinia, 2, 6, Boehringer-Ingelheim, 2, 6, Bristol Myers and Squibb, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Genentech, 2, 6, Guidepoint, 2, 6, Idorsia, 2, 6, Janssen, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 2, 6, Sanofi, 2, 6, Takeda, 2, 6.

To cite this abstract in AMA style:

Alongi A, Brunner H, Ravelli A, Avcin T, Beresford M, BURGOS-VARGAS R, Cuttica R, Khubchandani R, laxer R, Özen S, Petty R, Wallace C, Wulffraat N, Magni-Manzoni S, Jelusic M, Consolaro A, anton J, Horneff G, Glerup M, Filocamo G, Simonini G, CIVINO A, Remesal A, Scala S, Pistorio A, Lovell D, Martini A, Ruperto N. An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/an-international-delphi-survey-for-the-definition-of-new-classification-criteria-for-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-international-delphi-survey-for-the-definition-of-new-classification-criteria-for-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology